Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
INNPF
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
nasdaq.comPOSITIVO
Innocan Pharma To List On NYSE American With Concurrent Offering
(RTTNews) - Innocan Pharma (INNPF) announced that it anticipates to list on NYSE American on or around January 7, 2026. Innocan is also conducting a concurrent offering of its securities. Innocan expects that its common shares will continu…
Innocan Pharma Announces Details of Proposed Share Consolidation
HERZLIYA, Israel and CALGARY, Alberta, Aug. 29, 2025 /CNW/ -- Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that further to its press release dated July 23, 2025, it wi…
Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million
NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HERZLIYA, Israel and CALGARY, Alberta, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Innocan Pharma Corporation (the “Company”) (CSE: INNO) (FSE: IP4) (O…
Innocan Pharma Reports Successful Results of Efficacy Test for Vaginal Derma Product
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 23, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative…
Innocan Pharma Announces Launch of CBD Veterinary Commercialization Team
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 17, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative…
Innocan Pharma Announces First Patent Grant in the United States
This is the first fully granted patent of Innocan in the United States The Patent covers Innocan's proprietary cannabis-based pain relief topical This serves as an indication of Innocan's growing intellectual property portfolio Herzliya, I…
Innocan Pharma Reports Clinical Success in Canine Compassionate Care Trial
"Lady", an 11-year-old female dog was presented to Innocan labs suffering from severe autoimmune mediated polyarthritis. Lady was treated with Glycoflex, steroids, and hydrotherapy, but still suffered pain and had difficulty walking more t…
Innocan Pharma Provides Annual "State of the Business" Update
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 16, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovati…
Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovati…
Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovati…
Mr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 18, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovat…
Canadian Securities Exchange Reports October 2022 Performance Figures
Global Business Development Efforts Continue in Las Vegas and Israel Toronto, Ontario--(Newsfile Corp. - November 15, 2022) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market statistics for the month of…
Innocan Pharma Goes Live with Priority(TM) ERP System
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 9, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovativ…
Innocan Pharma to Participate in IR Labs' Investor Webinar on November 2, 2022
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovativ…
Innocan Pharma to Participate in the Luxury Meets CBD Conference on October 20 & 21 in New York
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 13, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) a pharmaceutical tech company focusing on developing innovative drug…
Innocan Pharma's Patent Application for Treatment of Psoriasis of the Scalp Reached National Phase
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focusing on developing innovative drug…
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 21, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative dru…
Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment
A 4-year-old intact male border collie dog with a body weight of 22 kg was suffering from refractory idiopathic (drug-resistant) epilepsy The dog was frequently hospitalized to stop seizure clusters Following treatment using Innocan's LPT…
Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug…
Innocan Pharma Announces Q2 2022 Results with 70% Annual Increase in Cash Balance and 70% Increase in Working Capital
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 30, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to report its financial results for the quarter ended June…
Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology
6 dogs suffering from osteoarthritis and lameness demonstrated CBD concentrations 6 weeks after a single injection Pain and well-being scores improved following treatment Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 17,…
Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform
First results from a study on dogs showed close to 100% bioavailability of CBD using Innocan's LPT technology This is compared to 6.5-20% bioavailability in humans when administered orally Herzliya, Israel and Calgary, Alberta--(Newsfile C…
Innocan Pharma Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 5, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT…
Innocan Pharma Files PCT Patent Application for Diabetic Symptoms
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT)…
Former Dexcel Pharma Analytical Chemist to Join Innocan Pharma LPT Pharmaceutical R&D Team as it is Moving Forward with the LPT Development
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 12, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has appointed Nissim Vasilevski as Analy…
Innocan Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures On a Dog using LPT: "Since The Last LPT injection, Paco (dog) Has Not Had a Seizure for Over 10 weeks"
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce positive results in a preclinical trial involving…
Innocan Reports Successful Preclinical Dog-Trial Results Regarding Pain Management: "It Was as If a New Dog Came into Our Lives"
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 24, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce successful preclinical trials in dogs with osteo…
Innocan Pharma Announces Filing of PCT Patent Application for Vaginal Atrophy Treatment
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new PCT patent application e…
Innocan Reports Successful Preliminary Trial Results Regarding Epilepsy in Dogs
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 10, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the successful preliminary results of a small-sc…
Innocan Pharma Announces Q1 2022 Results with 215% Increase in Cash Balance and 200% Increase in Working Capital
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 30, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to report its financial results for the quarter ended March 31,…
Innocan Pharma Obtains Receipt for Final Base Shelf Prospectus
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed and obtained a receipt for a fi…
Innocan Pharma Announces the Successful Publication of a New Patent Application of Its New Sustained-Release (LPC) CBD Formulation
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that an International Patent Application ("PCT")…
Innocan Pharma's Compassionate Care Treatment for Dogs
A Case Report Published in Frontiers in Veterinary Science Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to…
Innocan Pharma's Case Report Accepted to the 25M Readers of Frontiers Veterinary Scientific Journal
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to report the "accepted for publication" of a Case Report…
Innocan Pharma Reports a Successful FDA-Required Characterization of Highly CBD-Loaded Liposome Platform
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 28, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), is pleased to report the successful completion of Innocan's CBD Liposom…
Innocan Pharma Reports a Positive Result from the Use of Its CBD LPT on a Dog Suffering from Osteoarthritis
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 8, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that Innocan's CBD LPT injection provided as a…